

# CHAC technology CELLBCOSTER®

## **CELLBOOSTER®** Hair

Results of the clinical trial on healthy subjects



### Rationale of the clinical trial

Fighting hair loss & Strengthening hair follicles to improve hair density and quality

suisselle •



Hair aging: and if restoring nutrients into the scalp may help to fight against hair loss and stimulate their growth by acting on hair follicles?

### THE FOUR MAIN CAUSES OF HAIR LOSS<sup>1</sup>

#### **Hormonal**

- thyroid imbalance
- high testosterone
- dihydrotestosterone (DHT)
- polycystic ovarian
- syndrome (PCOS)insulin resistance
- estrogen dominance
- high cortisol

#### **Environmental**

- heavy metal toxicity
- chemical
   treatments
- mites

HORMONESBALANCE.COM

### **Micronutrient Deficiencies**

- vitamin B12
- biotin
- T) iron
- zinc • silica
  - gamma linolenic acid (GLA)
- lack of protein

#### <u>Autoimmunity</u>

• alopecia areata

If a product that contains these nutrients can be injected into the scalp, it should be possible to reduce hair loss and stimulate their growth.

1. https://hormonesbalance.com/articles/causes-of-hair-loss-in-women-and-potential-treatments/

## CELLBCOSTER® HAIR

suisselle •



Device designed for strengthening hair follicles, improving hair growth and microcirculation. It restores scalp skin structure and provides hair fiber restructuring.

✓ Hair growth acceleration
 ✓ Nourishes the scalp and fortifies follicles
 ✓ Prevents hair loss and graying

BOX 6 X 3 ml vials

## CHAC technology CELLBCOSTER® HAIR

suisselle •

### **INDICATIONS:**

- Non cicatricial alopecia,
- Alopecia areata,
- Androgenic alopecia,
- Damaged hair shaft (brittle, dull color, split ends),
- Premature graying,
- Seborrhea, psoriasis.


### **TREATMENT AREAS:**

Epidermis and dermis of:

- The scalp (near hair roots according to the mesotherapy applied technique).



In a few more details



- Nourishes the scalp and fortifies follicles,
  - ✓ Accelerates hair growth,
  - ✓ Prevents hair loss and graying.




suisselle •



suisselle

#### **Study purpose**

The objective of this study was to clinically assess the effect on hair density and hair quality after 6 sessions of CELLBOOSTER® HAIR injections on 26 healthy subjects, equally shared between men and women.



#### Patient treatments, follow-up & assessments

#### Assessments

- Hair quality clinical analysis:
  - Thickness,
  - Shine,
  - Hair loss
- Hair density & thickness improvement:
  - Scoring on macrophotography with Proscope x30
- Hair Shine:
  - Measurement with Glossymeter
- Effect of the product:
  - Scalp photographies by LifeViz 2D mini®
- Subject satisfaction (self assessment) and GAIS (global aesthetic improvement scale)
- Tolerance
  - Check of the absence of undesirable events at each visit.
  - Each adverse event was reported within 48 hours and was included in the study report.

1. GREDECO (groupe de recherche et d'évaluation en dermatologie et cosmétique). Final report: "clinical evaluation of the use of Cellbooster® hair (stabilized skin booster using the CHAC technology) on healthy volunteers. July 2023.

### **CELLBOOSTER®** Hair Clinical trial: methodology<sup>1</sup>

suisselle

#### **Patient inclusion**

#### ✓ Inclusion criteria

#### General criteria:


- Subjects able to follow the trial procedures,
- Subjects giving their free and written consent after oral and written information about the study,

#### Specific criteria:

- Women or men, age over 18 years old,
- For men, qualification by the Norwood-Hamilton scale: class 2a, 3, 3a or 3a vertex,
- For women, qualification by the Ludwig scale: type 1 or 2,
- Women agreed to perform a pregnancy test (for women who can procreate a pregnancy test will be performed before each injection),
- Low to moderate capillary density,
- Subject not using care (topical or systemic) intended for hair growth/improvement,
- Subject agreeing not to be exposed to the sun for the duration of the study.

#### Norwood-Hamilton scale





#### ✓ Principal exclusion criteria - subjects with:

#### General criteria:

- Currently participating in another clinical study related to pharmaceuticals or medical devices or subject in a period of exclusion from a clinical study,
- Facial injections/implants of any non-absorbable filler in his or her lifetime,
- Pregnant or lactating woman,
- Often exposed to the sun or UV during the last 15 days.


#### Allergies & inflammatory condition or other risk of infections:


- History of multiple severe allergies or anaphylactic shock,
- Known hypersensitivity to hyaluronic acid or to chlorhexidine,
- Tendency to develop inflammatory skin reactions or hypertrophic scars,
- An inflammatory skin reaction on or near the area to be treated (according to the opinion of the investigator),
- History of streptococcal disease (recurrent angina, rheumatic fever),
- Skin pathology, or an acute inflammatory reaction or bacterial or viral infection, at the study area level, or seen 6 weeks after the end of such an episode,
- Epilepsy not controlled by treatment,
- General pathology, skin pathology, dermatosis, acute or chronic systemic disease, and/or taking general or topical treatment that in the opinion of the investigator may interfere with the treatment or compromise the subject's participation in the study,
- Dermatological diseases that can reach the scalp (for example: pelade or lichen planus),
- Endocrine disruption mainly affecting the thyroid and more specifically hypothyroidism.

#### **Concomitant treatments:**


- Oral/injectable corticosteroid (or not stopped for ≥ 3 months). Inhaled corticosteroids are allowed as well as topical corticosteroid therapy not involving study areas,
- Concomitant treatment (or not stopped for ≥ 1 year) of immunosuppressant or chemotherapy A
  history of less than 12 months of radiation therapy at the study area level or of autoimmune
  pathology or connective tissue,
- Aspirin or anti-coagulants in regular doses during the past 15 days.

1. GREDECO (groupe de recherche et d'évaluation en dermatologie et cosmétique). Final report: "clinical evaluation of the use of Cellbooster® hair (stabilized skin booster using the CHAC technology) on healthy volunteers. July 2023.







Statistical analyses were performed with the Friedman test.



\* Not significant Statistical analyses were performed with the Friedman test.



Statistical analyses were performed with the Friedman test.




Statistical analyses were performed with the Friedman test.




### **CELLBOOSTER®** Hair: for more density


A significant improvement of hair density 3 weeks after the injection protocol (6 treatments)

Example of obtained results






Statistical analyses were performed with the Friedman test.





### **CELLBOOSTER®** Hair: a high satisfaction of subjects after 6 injections


Patient appraisal on product benefits after 6 injections (% of patients who "completely agree" or "rather agree" on quality of their hair – answer gathered with a self questionnaire)



A very high satisfaction of the subjects regarding the benefits of CELLBOOSTER® Hair



### **CELLBOOSTER®** Hair: a huge improvement of the hair appearance




Patient opinion on the GAIS\* asking about the improvement of their hair


89% of patients found their hair improved or even much improved/very much improved after 6 injections of CELLBOOSTER® Hair

GAIS: Global aesthetic improvement scale. Very much improved: Optimal cosmetic result for the implant in this subject. Much improved: Marked improvement in appearance from the initial condition, but not completely optimal for this subject. Improved: Obvious improvement in appearance from the initial condition. No change: The appearance is essentially the same as baseline. Worse: Obvious degradation in appearance from the initial condition.

















































### **CELLBOOSTER®** Hair: Conclusion

A strong clinical trial that allows 3 weeks after a 6 injections protocol to observe that CELLBOOSTER® Hair leads to :

